{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "increases_activity",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "uniprot:Q38424",
      "entity_text" : "ALT",
      "entity_type" : "protein"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "uniprot:Q38424",
      "entity_text" : "ALT",
      "features" : [ {
        "modification_type" : "unknown",
        "feature_type" : "modification"
      } ],
      "entity_type" : "gene_or_gene_product"
    },
    "hypothesis_information" : false
  },
  "verbose_text" : "Consequently, the patient 's clinical condition and ALT level (and in the case of ALT elevation also the HBV-DNA level) should be monitored for six months after the withdrawal of the drug.",
  "reading_complete" : "2020-08-03T18:26:01Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-03T18:20:40Z",
  "trigger" : "elevation",
  "evidence" : [ "ALT level (and in the case of ALT elevation" ],
  "pmc_id" : "5497479",
  "score" : 0
}